

# Nabeel B Nabulsi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1499126/publications.pdf>

Version: 2024-02-01

147  
papers

6,112  
citations

76326

40  
h-index

88630

70  
g-index

149  
all docs

149  
docs citations

149  
times ranked

5904  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Imaging synaptic density in the living human brain. <i>Science Translational Medicine</i> , 2016, 8, 348ra96.  | 12.4 | 343       |
| 2  | Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 316.   | 11.0 | 304       |
| 3  | Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. <i>JAMA Neurology</i> , 2018, 75, 1215.   | 9.0  | 304       |
| 4  | Lower synaptic density is associated with depression severity and network alterations. <i>Nature Communications</i> , 2019, 10, 1529.  | 12.8 | 277       |
| 5  | Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12468-12473.  | 7.1  | 265       |
| 6  | Synthesis and Preclinical Evaluation of <sup>11</sup> C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. <i>Journal of Nuclear Medicine</i> , 2016, 57, 777-784.   | 5.0  | 197       |
| 7  | The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [ <sup>11</sup> C]PBR28 PET study. <i>Brain, Behavior, and Immunity</i> , 2013, 33, 131-138.  | 4.1  | 180       |
| 8  | In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. <i>Alzheimer's and Dementia</i> , 2020, 16, 974-982.   | 0.8  | 170       |
| 9  | Sex Differences in the Brain's Dopamine Signature of Cigarette Smoking. <i>Journal of Neuroscience</i> , 2014, 34, 16851-16855.  | 3.6  | 145       |
| 10 | Kinetic evaluation and test-retest reproducibility of [ <sup>11</sup> C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 2041-2052. | 4.3  | 143       |
| 11 | Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. <i>Epilepsia</i> , 2016, 57, 201-209.   | 5.1  | 130       |
| 12 | PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[ <sup>11</sup> C]O-methylreboxetine and HRRT. <i>Synapse</i> , 2010, 64, 30-38.  | 1.2  | 112       |
| 13 | Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. <i>Annals of Neurology</i> , 2020, 87, 329-338.   | 5.3  | 112       |
| 14 | Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8390-8395.   | 7.1  | 107       |
| 15 | Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [ <sup>11</sup> C]-(+)-PHNO. <i>Psychopharmacology</i> , 2016, 233, 3503-3512.  | 3.1  | 101       |
| 16 | PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. <i>Neuroscience Letters</i> , 2019, 691, 44-50.  | 2.1  | 85        |
| 17 | Kinetic Modeling of the Serotonin 5-HT <sub>1B</sub> Receptor Radioligand [ <sup>11</sup> C]P943 in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 196-210.  | 4.3  | 83        |
| 18 | In Vivo Ketamine-Induced Changes in [ <sup>11</sup> C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. <i>Biological Psychiatry</i> , 2015, 77, 266-275.   | 1.3  | 82        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Synthesis and Evaluation of <sup>11</sup> C-LY2795050 as a $\mu$ -Opioid Receptor Antagonist Radiotracer for PET Imaging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 455-463.  | 5.0  | 80        |
| 20 | Assessment of a white matter reference region for <sup>11</sup> C-UCB-J PET quantification. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1890-1901.  | 4.3  | 77        |
| 21 | Affinity and selectivity of [ <sup>11</sup> C]â€(+)-â€PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. <i>Synapse</i> , 2012, 66, 489-500.   | 1.2  | 74        |
| 22 | Effects of age, BMI and sex on the glial cell marker TSPO â€” a multicentre [ <sup>11</sup> C]PBR28 HRRT PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2329-2338.   | 6.4  | 70        |
| 23 | Synthesis and <i>in Vivo</i> Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1544-1554.  | 3.5  | 70        |
| 24 | Imaging Glutamate Homeostasis in Cocaine Addiction with the Metabotropic Glutamate Receptor 5 Positron Emission Tomography Radiotracer [ <sup>11</sup> C]ABP688 and Magnetic Resonance Spectroscopy. <i>Biological Psychiatry</i> , 2014, 75, 165-171.           | 1.3  | 66        |
| 25 | First-in-Human Evaluation of <sup>18</sup> F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. <i>Journal of Nuclear Medicine</i> , 2021, 62, 561-567.   | 5.0  | 60        |
| 26 | PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. <i>Nature Communications</i> , 2020, 11, 2360.   | 12.8 | 56        |
| 27 | Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [ <sup>11</sup> C]UCBâ€€. <i>Alzheimer's and Dementia</i> , 2022, 18, 2527-2536.   | 0.8  | 55        |
| 28 | Evaluation of the agonist PET radioligand [ <sup>11</sup> C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, testâ€“retest reproducibility and receptor occupancy by the antagonist PF-04455242. <i>NeuroImage</i> , 2014, 99, 69-79. | 4.2  | 54        |
| 29 | Association of A $\beta$ 2 deposition and regional synaptic density in early Alzheimerâ€™s disease: a PET imaging study with [ <sup>11</sup> C]UCB-J. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.  | 6.2  | 53        |
| 30 | Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [ <sup>11</sup> C]UCBâ€€ positron emission tomography study. <i>Epilepsia</i> , 2020, 61, 2183-2193.  | 5.1  | 51        |
| 31 | In vivo evidence of lower synaptic vesicle density in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 7690-7698.  | 7.9  | 51        |
| 32 | Evaluation of [ <sup>11</sup> C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. <i>NeuroImage</i> , 2011, 56, 268-279.   | 4.2  | 50        |
| 33 | Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. <i>Journal of Nuclear Medicine</i> , 2014, 55, 595-601.  | 5.0  | 50        |
| 34 | In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [ <sup>11</sup> C]ABP688 and [ <sup>18</sup> F]FPEB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2716-2727.                              | 4.3  | 49        |
| 35 | Receptor Occupancy of the $\mu$ -Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer <sup>11</sup> C-LY2795050. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 260-266.                  | 2.5  | 47        |
| 36 | Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 449-456.  | 1.5  | 47        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. <i>Epilepsia</i> , 2019, 60, 958-967.                   | 5.1 | 45        |
| 38 | Evaluation of <sup>11</sup> C-BU99008, a PET Ligand for the Imidazoline <sub>2</sub> Binding Sites in Rhesus Brain. <i>Journal of Nuclear Medicine</i> , 2014, 55, 838-844.   | 5.0 | 44        |
| 39 | Age-related changes in binding of the D2/3 receptor radioligand [ <sup>11</sup> C](+)PHNO in healthy volunteers. <i>NeuroImage</i> , 2016, 130, 241-247.  | 4.2 | 43        |
| 40 | Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. <i>Biological Psychiatry</i> , 2018, 84, 413-421. | 1.3 | 43        |
| 41 | Comparison of [ <sup>11</sup> C]UCB-J and [ <sup>18</sup> F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2395-2409.                          | 4.3 | 43        |
| 42 | Studies of the metabotropic glutamate receptor 5 radioligand [ <sup>11</sup> C]ABP688 with N-acetylcysteine challenge in rhesus monkeys. <i>Synapse</i> , 2013, 67, 489-501.  | 1.2 | 42        |
| 43 | Kinetic Modeling of <sup>11</sup> C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1818-1825.                 | 4.3 | 42        |
| 44 | Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[ <sup>11</sup> C]O-methylreboxetine. <i>NeuroImage</i> , 2014, 86, 306-310.  | 4.2 | 41        |
| 45 | High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [ <sup>11</sup> C]P943. <i>Nuclear Medicine and Biology</i> , 2010, 37, 205-214.   | 0.6 | 40        |
| 46 | Microglial depletion and activation: A [ <sup>11</sup> C]PBR28 PET study in nonhuman primates. <i>EJNMMI Research</i> , 2017, 7, 59.  | 2.5 | 39        |
| 47 | OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. <i>Journal of Affective Disorders</i> , 2016, 196, 87-96.   | 4.1 | 38        |
| 48 | Synthesis and in vivo evaluation of [ <sup>18</sup> F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1952-1965.                  | 6.4 | 38        |
| 49 | PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age. <i>Neuropsychopharmacology</i> , 2018, 43, 2539-2547.  | 5.4 | 37        |
| 50 | Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. <i>Neuropsychopharmacology</i> , 2019, 44, 1720-1727.   | 5.4 | 36        |
| 51 | Test-Retest Reproducibility of Binding Parameters in Humans with <sup>11</sup> C-LY2795050, an Antagonist PET Radiotracer for the $\mu$ Opioid Receptor. <i>Journal of Nuclear Medicine</i> , 2015, 56, 243-248.                  | 5.0 | 35        |
| 52 | Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging Study. <i>Nicotine and Tobacco Research</i> , 2018, 20, 425-433.                                  | 2.6 | 35        |
| 53 | First-in-Human Assessment of <sup>11</sup> C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 553-560.   | 5.0 | 35        |
| 54 | Determination of the In Vivo Selectivity of a New $\mu$ -Opioid Receptor Antagonist PET Tracer <sup>11</sup> C-LY2795050 in the Rhesus Monkey. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1668-1674.                          | 5.0 | 34        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Quantification of myocardial blood flow with <sup>82</sup> Rb: Validation with <sup>15</sup> O-water using time-of-flight and point-spread-function modeling. <i>EJNMMI Research</i> , 2016, 6, 68.  | 2.5 | 34        |
| 56 | Age-Related Change in 5-HT <sub>6</sub> Receptor Availability in Healthy Male Volunteers Measured with <sup>11</sup> C-GSK215083 PET. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1445-1450.  | 5.0 | 34        |
| 57 | In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11490-11495.   | 7.1 | 34        |
| 58 | Synthesis and Preclinical Evaluation of an <sup>18</sup> F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [ <sup>18</sup> F]SynVesT-2. <i>ACS Chemical Neuroscience</i> , 2020, 11, 592-603.  | 3.5 | 34        |
| 59 | PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 205-14.   | 1.0 | 34        |
| 60 | Regional and source-based patterns of [ <sup>11</sup> C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D <sub>2</sub> and D <sub>3</sub> receptor availability in cocaine-use disorder. <i>NeuroImage</i> , 2017, 148, 343-351.   | 4.2 | 32        |
| 61 | Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.  | 7.9 | 32        |
| 62 | Determination of In Vivo <i>B<sub>max</sub></i> and <i>K<sub>d</sub></i> for <sup>11</sup> C-GR103545, an Agonist PET Tracer for <sup>18</sup> F-Opioid Receptors: A Study in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2013, 54, 600-608. | 5.0 | 31        |
| 63 | Determination of receptor occupancy in the presence of mass dose: [ <sup>11</sup> C]GSK189254 PET imaging of histamine H <sub>3</sub> receptor occupancy by PF-03654746. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1095-1107.     | 4.3 | 31        |
| 64 | PET imaging of mGluR5 in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 15.  | 6.2 | 29        |
| 65 | Cortical <sup>125</sup> I-amyloid burden, gray matter, and memory in adults at varying APOE $\epsilon$ 4 risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 207-214.   | 3.1 | 28        |
| 66 | Binding of the synaptic vesicle radiotracer [ <sup>11</sup> C]UCB-J is unchanged during functional brain activation using a visual stimulation task. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1067-1079.                         | 4.3 | 28        |
| 67 | [ <sup>11</sup> C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2993-3001.                           | 3.0 | 27        |
| 68 | First-in-Human Assessment of the Novel PDE2A PET Radiotracer <sup>18</sup> F-PF-05270430. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1388-1395.  | 5.0 | 27        |
| 69 | The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. <i>Biological Psychiatry</i> , 2019, 86, 864-871.   | 1.3 | 27        |
| 70 | Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. <i>Neuropsychopharmacology</i> , 2019, 44, 2205-2211.  | 5.4 | 27        |
| 71 | [ <sup>11</sup> C]GR103545: novel one-pot radiosynthesis with high specific activity. <i>Nuclear Medicine and Biology</i> , 2011, 38, 215-221.   | 0.6 | 26        |
| 72 | Age Effects on Serotonin Receptor 1B as Assessed by PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1411-1414.   | 5.0 | 26        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Kappa opioid receptor binding in major depression: A pilot study. <i>Synapse</i> , 2018, 72, e22042.  | 1.2 | 26        |
| 74 | Imaging human brown adipose tissue under room temperature conditions with <sup>11</sup> C-MRB, a selective norepinephrine transporter PET ligand. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 747-755.   | 3.4 | 25        |
| 75 | A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [ <sup>11</sup> C](+)PHNO. <i>Drug and Alcohol Dependence</i> , 2015, 154, 167-173.  | 3.2 | 25        |
| 76 | Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 111, 44-53.   | 3.1 | 25        |
| 77 | Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. <i>Molecular Psychiatry</i> , 2022, 27, 2273-2281.   | 7.9 | 25        |
| 78 | Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5056-5059.  | 2.2 | 24        |
| 79 | Assessment of test-retest reproducibility of [ <sup>18</sup> F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1327-1338.                         | 6.4 | 23        |
| 80 | Evaluation of PET Brain Radioligands for Imaging Pancreatic $\beta$ -Cell Mass: Potential Utility of <sup>11</sup> C-(+)-PHNO. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1249-1254.  | 5.0 | 22        |
| 81 | Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. <i>Neuropsychopharmacology</i> , 2019, 44, 1714-1719.   | 5.4 | 22        |
| 82 | Assessing the sensitivity of [ <sup>11</sup> C]p943, a novel 5-HT <sub>1B</sub> radioligand, to endogenous serotonin release. <i>Synapse</i> , 2011, 65, 1113-1117.   | 1.2 | 21        |
| 83 | PET Imaging of Pancreatic Dopamine D <sub>2</sub> and D <sub>3</sub> Receptor Density with <sup>11</sup> C-(+)-PHNO in Type 1 Diabetes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 570-576.   | 5.0 | 19        |
| 84 | Simplified Quantification of <sup>11</sup> C-UCB-J PET Evaluated in a Large Human Cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 418-421.   | 5.0 | 19        |
| 85 | Tracer Kinetic Modeling of [ <sup>11</sup> C]AFM, a New PET Imaging Agent for the Serotonin Transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1886-1896.  | 4.3 | 17        |
| 86 | Evaluation of <sup>11</sup> C-LSN3172176 as a Novel PET Tracer for Imaging M <sub>1</sub> Muscarinic Acetylcholine Receptors in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1147-1153.  | 5.0 | 17        |
| 87 | In vivo 5-HT <sub>6</sub> and 5-HT <sub>2A</sub> receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [ <sup>11</sup> C]GSK215083 PET. <i>Psychiatry Research - Neuroimaging</i> , 2020, 295, 111007. | 1.8 | 17        |
| 88 | Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. <i>Molecular Psychiatry</i> , 2021, 26, 5053-5060.   | 7.9 | 17        |
| 89 | Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand <sup>11</sup> C-BMT-136088 for Lung Imaging in Rhesus Monkeys. <i>Journal of Nuclear Medicine</i> , 2018, 59, 327-333.  | 5.0 | 16        |
| 90 | Quantification of Positron Emission Tomography Data Using Simultaneous Estimation of the Input Function: Validation with Venous Blood and Replication of Clinical Studies. <i>Molecular Imaging and Biology</i> , 2019, 21, 926-934.                                | 2.6 | 16        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [ <sup>18</sup> F]SDM-16. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1482-1496.             | 6.4 | 16        |
| 92  | Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory [ <sup>11</sup> C]CBT positron emission tomography study in humans. <i>Addiction Biology</i> , 2022, 27, e13123.   | 2.6 | 16        |
| 93  | Preclinical Evaluation of [ <sup>18</sup> F]-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1448-1453.  | 5.0 | 13        |
| 94  | Measuring the effects of ketamine on mGluR5 using [ <sup>18</sup> F]FPEB and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2254-2264.   | 4.3 | 13        |
| 95  | The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [ <sup>11</sup> C]FLB457 PET Study. <i>Neuropsychopharmacology</i> , 2018, 43, 1052-1058.  | 5.4 | 12        |
| 96  | [ <sup>11</sup> C]Methionine and [ <sup>11</sup> C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. <i>Molecular Imaging</i> , 2020, 19, 153601212096866.   | 1.4 | 12        |
| 97  | Imaging the Enzyme 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer [ <sup>11</sup> C]-AS2471907 in Human Brain. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1140-1146.                                 | 5.0 | 11        |
| 98  | First in-human PET study and kinetic evaluation of [ <sup>18</sup> F]AS2471907 for imaging 11 $\beta$ -hydroxysteroid dehydrogenase type 1. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 695-704.                                   | 4.3 | 10        |
| 99  | Kinetic Modeling and Test-Retest Reproducibility of [ <sup>11</sup> C]-EKAP and [ <sup>11</sup> C]-FEKAP, Novel Agonist Radiotracers for PET Imaging of the $\mu$ -Opioid Receptor in Humans. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1636-1642. | 5.0 | 10        |
| 100 | Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [ <sup>18</sup> F]FPEB PET. <i>NeuroImage</i> , 2021, 238, 118217.   | 4.2 | 10        |
| 101 | PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.   |     | 10        |
| 102 | Imaging brain cortisol regulation in PTSD with a target for 11 $\beta$ -hydroxysteroid dehydrogenase type 1. <i>Journal of Clinical Investigation</i> , 2021, 131, .  | 8.2 | 10        |
| 103 | Body Mass Index and Age Effects on Brain 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 1124-1131.   | 2.6 | 9         |
| 104 | Inverse changes in raphe and cortical 5-HT <sub>1B</sub> receptor availability after acute tryptophan depletion in healthy human subjects. <i>Synapse</i> , 2020, 74, e22159.   | 1.2 | 9         |
| 105 | Separating dopamine D2 and D3 receptor sources of [ <sup>11</sup> C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. <i>NeuroImage</i> , 2020, 214, 116762.  | 4.2 | 9         |
| 106 | A multi species evaluation of the radiation dosimetry of [ <sup>11</sup> C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. <i>Nuclear Medicine and Biology</i> , 2017, 47, 56-61.                                | 0.6 | 8         |
| 107 | The Search for a Subtype-Selective PET Imaging Agent for the GABA <sub>A</sub> Receptor Complex: Evaluation of the Radiotracer [ <sup>11</sup> C]ADO in Nonhuman Primates. <i>Molecular Imaging</i> , 2017, 16, 153601211773125.                        | 1.4 | 8         |
| 108 | Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1200-1204.   | 5.0 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand <sup>11</sup> C-UCB-J. <i>EJNMMI Research</i> , 2020, 10, 83.   | 2.5 | 8         |
| 110 | 962. In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [ <sup>11</sup> C]UCB-J PET Imaging Study. <i>Biological Psychiatry</i> , 2017, 81, S389.  | 1.3 | 7         |
| 111 | Evaluation of ( <sup>18</sup> F)F <sup>18</sup> lutetium-specific binding: Implications for reference region approaches. <i>Synapse</i> , 2018, 72, e22016.  | 1.2 | 7         |
| 112 | Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107627.  | 3.2 | 7         |
| 113 | Longitudinal imaging of metabotropic glutamate 5 receptors during early and extended alcohol abstinence. <i>Neuropsychopharmacology</i> , 2021, 46, 380-385.   | 5.4 | 7         |
| 114 | Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer <sup>11</sup> C-TASP699. <i>Journal of Nuclear Medicine</i> , 2022, 63, 609-614.  | 5.0 | 7         |
| 115 | A modification to improve the reliability of <sup>11</sup> C]CN <sup>11</sup> production in the <sup>11</sup> C]GE radiochemistry system. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 592-595. | 1.0 | 5         |
| 116 | Quantitative projection of human brain penetration of the H <sub>3</sub> antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. <i>Xenobiotica</i> , 2017, 47, 119-126.            | 1.1 | 5         |
| 117 | PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. <i>Cerebral Cortex</i> , 2021, 31, 2787-2798.   | 2.9 | 5         |
| 118 | F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [ <sup>11</sup> C]UCB-J PET. <i>Biological Psychiatry</i> , 2018, 83, S296.      | 1.3 | 4         |
| 119 | Assessment of transient dopamine responses to smoked cannabis. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108920.   | 3.2 | 4         |
| 120 | Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3679-3691.  | 6.4 | 4         |
| 121 | Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, S145-S146.                          | 1.2 | 3         |
| 122 | Evaluation of quantitative modeling methods in whole-body, dynamic [ <sup>11</sup> C]-erlotinib PET. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 143-153.                                  | 1.0 | 3         |
| 123 | Feasibility of imaging synaptic density in the human spinal cord using [ <sup>11</sup> C]UCB-J PET. <i>EJNMMI Physics</i> , 2022, 9, 32.   | 2.7 | 3         |
| 124 | Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044211.                                | 0.8 | 2         |
| 125 | Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1348-1357.                 | 2.4 | 2         |
| 126 | Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [ <sup>18</sup> F]FPEB and PET. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, S96-S97.                               | 1.2 | 1         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | P1469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P501.   | 0.8 | 1         |
| 128 | In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037791.  | 0.8 | 1         |
| 129 | Validation of a simplified tissue-to-reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [11C]UCB-J PET. Alzheimer's and Dementia, 2020, 16, e045928.                      | 0.8 | 1         |
| 130 | Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [11C]PHNO PET. Drug and Alcohol Dependence, 2021, 220, 108514.  | 3.2 | 1         |
| 131 | Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal of Geriatric Psychiatry, 2021, 29, S119-S120.   | 1.2 | 1         |
| 132 | Nicotine patch alters patterns of cigarette smoking-induced dopamine release: Patterns relate to biomarkers associated with treatment response. Nicotine and Tobacco Research, 2022, , .  | 2.6 | 1         |
| 133 | P2365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P832.   | 0.8 | 0         |
| 134 | 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET. Journal of Clinical and Translational Science, 2018, 2, 3-4.   | 0.6 | 0         |
| 135 | IC403: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P8.   | 0.8 | 0         |
| 136 | IC4183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P152.  | 0.8 | 0         |
| 137 | S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGING. Schizophrenia Bulletin, 2019, 45, S310-S311.  | 4.3 | 0         |
| 138 | P4481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's and Dementia, 2019, 15, P1497. | 0.8 | 0         |
| 139 | IC4140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTITRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.  | 0.8 | 0         |
| 140 | PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037792.  | 0.8 | 0         |
| 141 | 11C-PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043584.  | 0.8 | 0         |
| 142 | Association between cerebral amyloid accumulation and synaptic density in Alzheimer's disease: A multitracers PET study. Alzheimer's and Dementia, 2020, 16, e043631.   | 0.8 | 0         |
| 143 | ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY. American Journal of Geriatric Psychiatry, 2020, 28, S123-S124.  | 1.2 | 0         |
| 144 | Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease. American Journal of Geriatric Psychiatry, 2021, 29, S47-S48.  | 1.2 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Imaging the Effect of Ketamine on Synaptic (SV2A) Density. <i>Biological Psychiatry</i> , 2021, 89, S35.   | 1.3 | 0         |
| 146 | Translational PET Imaging of Spinal Cord Injury with the Serotonin Transporter Tracer [11C]AFM. <i>Molecular Imaging and Biology</i> , 2022, , 1.  | 2.6 | 0         |
| 147 | Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PET. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, S26. | 1.2 | 0         |